RT Journal Article
SR Electronic
T1 Distinct Roles of Cholinergic Receptors in Small Cell Lung Cancer Cells
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 97
OP 106
VO 30
IS 1
A1 SHUXIANG ZHANG
A1 SHINSAKU TOGO
A1 KUNIHIKO MINAKATA
A1 TAO GU
A1 RINA OHASHI
A1 KEN TAJIMA
A1 AKIKO MURAKAMI
A1 SHINICHIRO IWAKAMI
A1 JIN ZHANG
A1 CANMAO XIE
A1 KAZUHISA TAKAHASHI
YR 2010
UL http://ar.iiarjournals.org/content/30/1/97.abstract
AB Background: Cholinergic receptors are expressed in small cell lung cancer (SCLC); however, the distinct functions of muscarinic cholinergic receptor 3 (mAChR3) and the nicotinic cholinergic receptor (nAChR) in SCLC have not yet been completely elucidated. Materials and Methods: RT-PCR and Western blotting were used to investigate the expression of cholinergic receptors. Flow cytometry was used to detect the integrin expression. Cell proliferation, adhesion and migration assays were carried out in vitro to determine the roles of the cholinergic receptors in SBC3 human SCLC cells. Results: Both mAChR3 and nAChR were expressed in the SBC3 cells. Acetylcholine iodide (Ach) stimulated SBC3 cell proliferation, adhesion and migration toward fibronectin (Fn). The mAChR3 antagonist, 4-diphenylacetoxy-N-methylpiperidine methiodide (4-DAMP), or the nAChR antagonist, mecamylamine hydrochloride (Meca), inhibited SBC3 cell proliferation in the presence or the absence of exogenous Ach. 4-DAMP abrogated cell adhesion and migration toward Fn induced by Ach, while Meca had no effect. Interestingly, Ach did not alter Fn receptor (αvβ1 or α5β1 integrin) expression, while anti-β1 integrin antibody or anti-αv and anti-α5 integrin antibody completely abrogated cell adhesion to Fn induced by Ach. Conclusion: Both mAChR3 and nAChR are expressed in SCLC. SBC3 cell proliferation is regulated in vitro through both cholinergic receptors. In contrast, SBC3 cell migration and adhesion toward Fn are modulated only by mAChR. Moreover, the stimulatory effects of Ach on cell adhesion and migration through mAChR3 are presumably modulated by functional alteration of αvβ1 and α5β1 integrin, but not by any variation in their expression. The mAChR3 antagonist may therefore be a beneficial therapeutic modality for SCLC patients, especially those with chronic obstructive pulmonary disease (COPD) as a comorbidity. Copyright© 2010 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved